Meridian Bioscience Inc.

NASDAQ:VIVO   9:56:34 AM EDT
21.28
+0.18 (+0.85%)
Products

U.S. FDA Says Magellan Diagnostics Recalls Leadcare II, Leadcare Plus, And Leadcare Ultra Blood Lead Tests Due To Risk Of Falsely Low Results

Published: 07/01/2021 22:34 GMT
Meridian Bioscience Inc. (VIVO) - :u.s. FDA Says Magellan Diagnostics Recalls Leadcare Ii, Leadcare Plus, and Leadcare Ultra Blood Lead Tests Due to Risk of Falsely Low Results.
U.S. FDA Says Identified Recalls by Magellan Diagnostics As a Class I Recall.
Further Company Coverage: Vivoo ((reuters.
Briefs@thomsonreuters.
Com;)).